List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7340188/publications.pdf Version: 2024-02-01



Тнамс V Рилм

#	Article	IF	CITATIONS
1	Proteomic analysis of cerebrospinal fluid extracellular vesicles: A comprehensive dataset. Journal of Proteomics, 2014, 106, 191-204.	2.4	222
2	On the beta-binomial model for analysis of spectral count data in label-free tandem mass spectrometry-based proteomics. Bioinformatics, 2010, 26, 363-369.	4.1	153
3	Proteomic Profiling of Mycobacterium tuberculosis Identifies Nutrient-starvation-responsive Toxin–antitoxin Systems. Molecular and Cellular Proteomics, 2013, 12, 1180-1191.	3.8	148
4	Workflow Comparison for Label-Free, Quantitative Secretome Proteomics for Cancer Biomarker Discovery: Method Evaluation, Differential Analysis, and Verification in Serum. Journal of Proteome Research, 2010, 9, 1913-1922.	3.7	126
5	Decoration of Outer Membrane Vesicles with Multiple Antigens by Using an Autotransporter Approach. Applied and Environmental Microbiology, 2014, 80, 5854-5865.	3.1	95
6	Exosomes Secreted by Apoptosis-Resistant Acute Myeloid Leukemia (AML) Blasts Harbor Regulatory Network Proteins Potentially Involved in Antagonism of Apoptosis. Molecular and Cellular Proteomics, 2016, 15, 1281-1298.	3.8	90
7	Colorectal cancer candidate biomarkers identified by tissue secretome proteome profiling. Journal of Proteomics, 2014, 99, 26-39.	2.4	81
8	Novel diagnostic cerebrospinal fluid biomarkers for pathologic subtypes of frontotemporal dementia identified by proteomics. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 2, 86-94.	2.4	68
9	iTRAQ-based Proteomics Profiling Reveals Increased Metabolic Activity and Cellular Cross-talk in Angiogenic Compared with Invasive Glioblastoma Phenotype. Molecular and Cellular Proteomics, 2009, 8, 2595-2612.	3.8	65
10	An accurate paired sample test for count data. Bioinformatics, 2012, 28, i596-i602.	4.1	63
11	Comparative Protein Profiling Reveals Minichromosome Maintenance (MCM) Proteins As Novel Potential Tumor Markers for Meningiomas. Journal of Proteome Research, 2010, 9, 485-494.	3.7	59
12	Cancer cells copy migratory behavior and exchange signaling networks via extracellular vesicles. EMBO Journal, 2018, 37, .	7.8	58
13	Proteomic and Functional Studies Reveal Detyrosinated Tubulin as Treatment Target in Sarcomere Mutation-Induced Hypertrophic Cardiomyopathy. Circulation: Heart Failure, 2021, 14, e007022.	3.9	58
14	The Proteome of the Locus Ceruleus in Parkinson's Disease: Relevance to Pathogenesis. Brain Pathology, 2012, 22, 485-498.	4.1	53
15	<scp>INKA</scp> , an integrative data analysis pipeline for phosphoproteomic inference of active kinases. Molecular Systems Biology, 2019, 15, e8250.	7.2	53
16	<i>iq</i> : an R package to estimate relative protein abundances from ion quantification in DIA-MS-based proteomics. Bioinformatics, 2020, 36, 2611-2613.	4.1	53
17	Feasibility of urinary extracellular vesicle proteome profiling using a robust and simple, clinically applicable isolation method. Journal of Extracellular Vesicles, 2017, 6, 1313091.	12.2	51
18	DPHL: A DIA Pan-human Protein Mass Spectrometry Library for Robust Biomarker Discovery. Genomics, Proteomics and Bioinformatics, 2020, 18, 104-119.	6.9	51

#	Article	IF	CITATIONS
19	Label-free mass spectrometry-based proteomics for biomarker discovery and validation. Expert Review of Molecular Diagnostics, 2012, 12, 343-359.	3.1	46
20	Proximal Fluid Proteome Profiling of Mouse Colon Tumors Reveals Biomarkers for Early Diagnosis of Human Colorectal Cancer. Clinical Cancer Research, 2012, 18, 2613-2624.	7.0	46
21	Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: a proteomic approach. Molecular Neurodegeneration, 2020, 15, 36.	10.8	46
22	Feasibility of label-free phosphoproteomics and application to base-line signaling of colorectal cancer cell lines. Journal of Proteomics, 2015, 127, 247-258.	2.4	45
23	Evaluation of different phospho-tyrosine antibodies for label-free phosphoproteomics. Journal of Proteomics, 2015, 127, 259-263.	2.4	43
24	Tumor Heterogeneity Underlies Differential Cisplatin Sensitivity in Mouse Models of Small-Cell Lung Cancer. Cell Reports, 2019, 27, 3345-3358.e4.	6.4	42
25	Face detection by aggregated Bayesian network classifiers. Pattern Recognition Letters, 2002, 23, 451-461.	4.2	41
26	Colorectal cancer derived organotypic spheroids maintain essential tissue characteristics but adapt their metabolism in culture. Proteome Science, 2014, 12, 39.	1.7	40
27	Novel Stool-Based Protein Biomarkers for Improved Colorectal Cancer Screening. Annals of Internal Medicine, 2017, 167, 855.	3.9	39
28	Microdissected pancreatic cancer proteomes reveal tumor heterogeneity and therapeutic targets. JCI Insight, 2020, 5, .	5.0	36
29	Proteomic analysis of gemcitabine-resistant pancreatic cancer cells reveals that microtubule-associated protein 2 upregulation associates with taxane treatment. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591984123.	3.2	35
30	Identification of Differentially Expressed Splice Variants by the Proteogenomic Pipeline Splicify. Molecular and Cellular Proteomics, 2017, 16, 1850-1863.	3.8	33
31	Proteins in stool as biomarkers for nonâ€invasive detection of colorectal adenomas with high risk of progression. Journal of Pathology, 2020, 250, 288-298.	4.5	33
32	Combined Expression of Plasma Thrombospondin-2 and CA19-9 for Diagnosis of Pancreatic Cancer and Distal Cholangiocarcinoma: A Proteome Approach. Oncologist, 2020, 25, e634-e643.	3.7	33
33	Prediction of outcome of non-small cell lung cancer patients treated with chemotherapy and bortezomib by time-course MALDI-TOF-MS serum peptide profiling. Proteome Science, 2009, 7, 34.	1.7	32
34	Genome-wide siRNA Screen Identifies the Radiosensitizing Effect of Downregulation of MASTL and FOXM1 in NSCLC. Molecular Cancer Therapeutics, 2015, 14, 1434-1444.	4.1	32
35	Sunitinib activates Axl signaling in renal cell cancer. International Journal of Cancer, 2016, 138, 3002-3010.	5.1	32
36	Phosphotyrosine-based-phosphoproteomics scaled-down to biopsy level for analysis of individual tumor biology and treatment selection. Journal of Proteomics, 2017, 162, 99-107.	2.4	31

#	Article	IF	CITATIONS
37	High-throughput and targeted in-depth mass spectrometry-based approaches for biofluid profiling and biomarker discovery. Biomarkers in Medicine, 2007, 1, 541-565.	1.4	30
38	Phosphotyrosine-based Phosphoproteomics for Target Identification and Drug Response Prediction in AML Cell Lines. Molecular and Cellular Proteomics, 2020, 19, 884-899.	3.8	29
39	Peptide-mediated â€~miniprep' isolation of extracellular vesicles is suitable for high-throughput proteomics. EuPA Open Proteomics, 2016, 11, 11-15.	2.5	28
40	Human Testis Phosphoproteome Reveals Kinases as Potential Targets in Spermatogenesis and Testicular Cancer. Molecular and Cellular Proteomics, 2019, 18, S132-S144.	3.8	26
41	Differential Detergent Extraction of Mycobacterium marinum Cell Envelope Proteins Identifies an Extensively Modified Threonine-Rich Outer Membrane Protein with Channel Activity. Journal of Bacteriology, 2013, 195, 2050-2059.	2.2	25
42	Proteomic Analysis of miR-195 and miR-497 Replacement Reveals Potential Candidates that Increase Sensitivity to Oxaliplatin in MSI/P53wt Colorectal Cancer Cells. Cells, 2019, 8, 1111.	4.1	25
43	Proteomics of Genetically Engineered Mouse Mammary Tumors Identifies Fatty Acid Metabolism Members as Potential Predictive Markers for Cisplatin Resistance. Molecular and Cellular Proteomics, 2013, 12, 1319-1334.	3.8	24
44	Proteomics of Mouse BRCA1-deficient Mammary Tumors Identifies DNA Repair Proteins with Potential Diagnostic and Prognostic Value in Human Breast Cancer. Molecular and Cellular Proteomics, 2012, 11, M111.013334-1-M111.013334-19.	3.8	23
45	Changes in the urinary extracellular vesicle proteome are associated with nephronophthisis-related ciliopathies. Journal of Proteomics, 2019, 192, 27-36.	2.4	22
46	Mass Spectrometry-Based Serum and Plasma Peptidome Profiling for Prediction of Treatment Outcome in Patients With Solid Malignancies. Oncologist, 2014, 19, 1028-1039.	3.7	21
47	Omics Analysis of Educated Platelets in Cancer and Benign Disease of the Pancreas. Cancers, 2021, 13, 66.	3.7	20
48	Sparse representation for coarse and fine object recognition. IEEE Transactions on Pattern Analysis and Machine Intelligence, 2006, 28, 555-567.	13.9	19
49	Proteome analysis of non-small cell lung cancer cell line secretomes and patient sputum reveals biofluid biomarker candidates for cisplatin response prediction. Journal of Proteomics, 2019, 196, 106-119.	2.4	18
50	Learning spatial relations in object recognition. Pattern Recognition Letters, 2006, 27, 1673-1684.	4.2	17
51	Loss of FLCN-FNIP1/2 induces a non-canonical interferon response in human renal tubular epithelial cells. ELife, 2021, 10, .	6.0	15
52	Object recognition with uncertain geometry and uncertain part detection. Computer Vision and Image Understanding, 2005, 99, 241-258.	4.7	14
53	Quantitative analysis of CDX2 protein expression improves its clinical utility as a prognostic biomarker in stage II and III colon cancer. European Journal of Cancer, 2021, 144, 91-100.	2.8	14
54	Secretome proteomics reveals candidate non-invasive biomarkers of <i>BRCA1</i> deficiency in breast cancer. Oncotarget, 2016, 7, 63537-63548.	1.8	14

#	Article	IF	CITATIONS
55	Evaluation of potential circulating biomarkers for prediction of response to chemoradiation in patients with glioblastoma. Journal of Neuro-Oncology, 2016, 129, 221-230.	2.9	13
56	Phosphoproteomic Characterization of Primary AML Samples and Relevance for Response Toward FLT3-inhibitors. HemaSphere, 2021, 5, e606.	2.7	12
57	Secreted protein markers in oral squamous cell carcinoma (OSCC). Clinical Proteomics, 2022, 19, 4.	2.1	12
58	Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma. Clinical Cancer Research, 2022, 28, 1595-1602.	7.0	12
59	Phosphoproteomic profiling of T cell acute lymphoblastic leukemia reveals targetable kinases and combination treatment strategies. Nature Communications, 2022, 13, 1048.	12.8	12
60	Kinase Inhibitor Treatment of Patients with Advanced Cancer Results in High Tumor Drug Concentrations and in Specific Alterations of the Tumor Phosphoproteome. Cancers, 2020, 12, 330.	3.7	11
61	Sex-Related Differences in Protein Expression in Sarcomere Mutation-Positive Hypertrophic Cardiomyopathy. Frontiers in Cardiovascular Medicine, 2021, 8, 612215.	2.4	11
62	Quadratic boosting. Pattern Recognition, 2008, 41, 331-341.	8.1	9
63	Proteomics of differential extraction fractions enriched for chromatin-binding proteins from colon adenoma and carcinoma tissues. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2014, 1844, 1034-1043.	2.3	8
64	Effects of Cancer Presence and Therapy on the Platelet Proteome. International Journal of Molecular Sciences, 2021, 22, 8236.	4.1	8
65	Longitudinal stability of urinary extracellular vesicle protein patterns within and between individuals. Scientific Reports, 2021, 11, 15629.	3.3	6
66	Feasibility of phosphoproteomics to uncover oncogenic signalling in secreted extracellular vesicles using glioblastoma-EGFRVIII cells as a model. Journal of Proteomics, 2021, 232, 104076.	2.4	5
67	Response and toxicity prediction by MALDI‶OFâ€MS serum peptide profiling in patients with nonâ€small cell lung cancer. Proteomics - Clinical Applications, 2016, 10, 743-749.	1.6	4
68	Quantitative Phosphoproteomic Analysis Reveals Dendritic Cell- Specific STAT Signaling After α2-3–Linked Sialic Acid Ligand Binding. Frontiers in Immunology, 2021, 12, 673454.	4.8	3
69	The influence of delay in mononuclear cell isolation on acute myeloid leukemia phosphorylation profiles. Journal of Proteomics, 2021, 238, 104134.	2.4	3
70	Selection of Protein Kinase Inhibitors Based on Tumor Tissue Kinase Activity Profiles in Patients with Refractory Solid Malignancies: An Interventional Molecular Profiling Study. Oncologist, 2018, 23, 1135.	3.7	2
71	Time dependent effect of cold ischemia on the phosphoproteome and protein kinase activity in fresh-frozen colorectal cancer tissue obtained from patients. Clinical Proteomics, 2021, 18, 8.	2.1	2
72	Lipopolysaccharideâ€regulated secretion of soluble and vesicleâ€based proteins from a panel of colorectal cancer cell lines. Proteomics - Clinical Applications, 2021, 15, 1900119.	1.6	2

#	Article	IF	CITATIONS
73	Phospho-Proteomic Profiling of T-Cell Acute Lymphoblastic Leukemia Identifies Targetable Kinase Activities and Novel Treatment Combination Strategies. Blood, 2020, 136, 14-15.	1.4	1
74	Phosphoproteomic Analysis of FLCN Inactivation Highlights Differential Kinase Pathways and Regulatory TFEB Phosphoserines. Molecular and Cellular Proteomics, 2022, 21, 100263.	3.8	1
75	O1â€06â€03: Proteomic Analysis of Extracellular Vesicles in Alzheimer's Disease Cerebrospinal FLUID. Alzheimer's and Dementia, 2016, 12, P186.	0.8	0
76	[P2–242]: PROTEOMICS IDENTIFICATION OF NOVEL CEREBROSPINAL FLUID BIOMARKER CANDIDATES OF DEMENTIA WITH LEWY BODIES. Alzheimer's and Dementia, 2017, 13, P704.	0.8	0
77	O3â€14â€03: IDENTIFICATION OF NOVEL CEREBROSPINAL FLUID BIOMARKER CANDIDATES FOR DEMENTIA WITH LEWY BODIES: A PROTEOMIC APPROACH. Alzheimer's and Dementia, 2018, 14, P1060.	H _{0.8}	0
78	Prediction of response to sunitinib in patients with advanced renal cell carcinoma (RCC) using mass spectrometry-based (phospho) proteomics Journal of Clinical Oncology, 2021, 39, e16556-e16556.	1.6	0
79	Response prediction by MALDI-TOF-MS serum peptide profiling of combination treatment with sorafenib and erlotinib in patients with non-small cell lung cancer Journal of Clinical Oncology, 2012, 30, e18094-e18094.	1.6	0
80	Mass spectrometry-based serum and plasma peptide profiling for prediction of treatment outcome in patients with cancer Journal of Clinical Oncology, 2014, 32, e22221-e22221.	1.6	0
81	Mass spectrometry-based phosphoproteomics of tumor needle biopsies from patients (pts) with advanced solid tumors during treatment with protein kinase inhibitors Journal of Clinical Oncology, 2016, 34, 11609-11609.	1.6	0
82	Comparison of phosphoproteomic profiles in left- and right-sided colorectal cancers Journal of Clinical Oncology, 2019, 37, 582-582.	1.6	0